The study also presented the first external validation and use in patients with early RA of six proposed screening strategies ...
MariTide is now progressing into phase 3 trials, with a focus on its long-term safety and efficacy. Amgen expects to apply ...
Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the ...
“This study reports that consuming a cocoa-based drink high in flavanols improves blood flow during sitting. It is already known that the consumption of flavanols improves measures of endothelial ...
Boehringer Ingelheim has announced that China's National Medical Products Administration (NMPA) has approved JASCAYD (nerandomilast) as an oral treatment option for idiopathic pulmonary ...
Boehringer Ingelheim’s Jascayd approved in China to treat idiopathic pulmonary fibrosis: Ingelheim, Germany Thursday, October 23, 2025, 12:00 Hrs [IST] Boehringer Ingelheim’s ...
Privately-held German drugmaker Boehringer Ingelheim’s Jascayd (nerandomilast) has been approved by China’s National Medical ...
Boehringer Ingelheim hired Ryan Donnelly as senior associate director of government affairs and public policy. Greg ...
Market is projected to grow from US$ 3.97 billion in 2024 to US$ 4.92 billion by 2033, at a CAGR of 2.42%. Factors driving ...
Pharmaceutical Technology on MSN
GSK targets Syndivia’s prostate cancer ADC in £268m buy
GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...
6d
JASCAYD® (nerandomilast) approved in China for the treatment of idiopathic pulmonary fibrosis (IPF)
Ingelheim, GermanyApproval is based on results from Phase III FIBRONEER™-IPF trial, which showed statistically significant improvements in the ...
Patients who depended on oral corticosteroids to care for their severe asthma experienced improvements in asthma control ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback